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ABSTRACT
The genetics of anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) is a complex area of investigation
because of the low frequency of AAVs, the rarity of familial
cases and the complexity of disease phenotypes. However,
recent studies have been able to gather signiﬁcant numbers of
patients, and multicentre collaborative efforts have allowed the
performance of two genome-wide association studies (GWASs).
Genetic association studies based on candidate gene approaches
and the two GWASs have greatly contributed to our current un-
derstanding of the genetic basis of AAV. The central role of
autoimmunity has been conﬁrmed by the signiﬁcant association
with HLA polymorphisms; interestingly, the three main AAV
subtypes are associated with distinct HLA variants, i.e. granulo-
matosis with polyangiitis (Wegener’s GPA) with HLA-DP1,
microscopic polyangiitis with HLA-DQ and eosinophilic GPA
(Churg-Strauss) with HLA-DRB4. GWASs also revealed that
polymorphic variants of genes encoding proteinase 3 (PR3), the
predominant antigenic target of ANCA in GPA, and its main
inhibitor, alpha-1 antitrypsin, are highly associated with GPA
and, even more signiﬁcantly, with PR3-ANCA positivity (re-
gardless of the clinical diagnosis); this emphasizes the central
pathogenic role of PR3 and humoral autoimmunity in PR3-
ANCA positive vasculitis. Finally, candidate gene approach
studies have shown associations with other variants involved in
autoimmunity, such as those belonging to the CTLA-4 and
PTPN22 genes, although these ﬁndings warrant replication in
larger studies. Additional studies are underway to better charac-
terize disease associations within the AAV spectrum, which
could provide new pathogenetic clues and possibly new treat-
ment targets.
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INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) refers to a group of small-vessel vasculitis,
including granulomatosis with polyangiitis (GPA, formerly
known as Wegener’s granulomatosis), microscopic polyangii-
tis (MPA) and eosinophilic GPA (EGPA, formerly Churg-
Strauss syndrome) [1]. GPA and MPA are characterized by an
extensive overlap in terms of clinical manifestations, mainly
due to the possible vasculitic involvement of virtually all organ
systems; however, the most frequent localizations are lung and
kidney with pulmonary haemorrhage and rapidly progressive
glomerulonephritis being the most severe manifestations [1].
Granulomatous involvement of the ear, nose and throat
(ENT) system and of the lung is a frequent clinical feature of
GPA and may represent the only localization in subgroups of
patients [1]. Because of the frequent clinical overlap, GPA and
MPA have been historically considered different ends of the
same disease spectrum and therefore included together in clin-
ical trials [2]. ANCA positivity is a feature of ∼90% of GPA
and MPA patients; ANCA is usually tested using indirect
immunoﬂuorescence, where two main patterns are observed,
cytoplasmic (C-ANCA) and perinuclear (P-ANCA), and then
conﬁrmed using ELISA, which in most cases shows reactivity
against proteinase 3 (PR3) or myeloperoxidase (MPO). GPA
is usually associated with C-ANCA, directed against PR3,
whereas MPA with P-ANCA, directed against MPO [3];
however, a signiﬁcant overlap does exist with regard to the
ANCA status; therefore although ANCA are often used to
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conﬁrm the diagnosis of AAV, ANCA speciﬁcity towards PR3
or MPO cannot be used to identify GPA versus MPA [4]. In
EGPA, the main disease characteristics are asthma, peripheral
eosinophilia, ENT involvement and eosinophil-rich lung inﬁl-
trates; vasculitic manifestations (e.g. glomerulonephritis, per-
ipheral neuropathy and purpura) are less prevalent than in
GPA and MPA and they appear to be more frequent in the
40% of EGPA patients that are ANCA-positive [3, 5].
Several candidate gene approach studies have been per-
formed over the years; however, the understanding in the ﬁeld
of AAV genetics has dramatically increased after the publica-
tion of two genome-wide association studies (GWASs). The
philosophy behind the GWAS is the interrogation of a high
number of single-nucleotide polymorphisms (SNPs) that
cover a big proportion of the human genome. This approach
may be very informative; however, to avoid spurious associa-
tions, a very stringent P-value is required forcing a multicentre
approach with big cohorts of patients. Two GWASs have been
performed in AAV: the ﬁrst conducted by the European Vascu-
litis Genetic Consortium (EVGC; 2687 cases of GPA and MPA,
as well as 6858 controls) [6] and the second by the US Vasculitis
Clinical Research Consortium (VCRC; 987 GPA cases and 2731
controls) [7].
In this review, we will discuss the main genetic associations
that have emerged in AAV, and what they have added to our
understanding of vasculitis. Tables 1 and 2 summarize the
main genetic associations in AAV derived from non-GWAS
and GWAS, respectively.
GENETIC ASSOCIATIONS WITH AAVS
HLA region
The role of the HLA region in autoimmunity is central.
Several associations with different HLA SNPs have been
shown, for instance, in rheumatoid arthritis and type 1 dia-
betes [24, 25]. When acting as risk factors, HLA SNPs may
promote positive selection of autoreactive T cells or prevent
their negative selection [26].
The strongest evidence of HLA association in AAV is with
the HLA-DPB1. This association has been initially described
in a cohort of 150 German GPA patients (P = 1.51 × 10−10, OR
3.91) [27] and subsequently conﬁrmed in an independent
group of 108 German GPA patients [28]; in a further analysis
of the combined cohort, the association remained signiﬁcant
only in the ANCA-positive patients (P = 1.26 × 10−22). This
ﬁnding was then conﬁrmed by the results of both GWASs: a
strong association of an SNP in the HLA-DPB1 area (OR 3.67,
P = 1.5 × 10−71) resulted from the EVGC GWAS [6] as well as
from the VCRC GWAS (OR 0.24, P = 1.91 × 10−50) [7]. The
different directions of the OR observed between the two
studies may be related to the different SNPs interrogated, the
frequencies of each SNP minor allele in patients and controls
or the modality of data analysis; nevertheless, both studies in-
dicate a highly signiﬁcant association between AAV and varia-
tions within HLA-DPB1.
Interestingly, a sub-analysis of the EVGC GWAS also showed
that this association was stronger in the PR3-ANCA-positive
subgroup (P = 6.2 × 10−89), independently of the clinical diagno-
sis, while this was not conﬁrmed in the MPO-ANCA-positive
subgroup. In the latter, a further analysis revealed an association
with an SNP in the HLA-DQ region (P = 2.1 × 10−08), which had
probably been masked by the small number of MPO-ANCA-
positive patients in the primary analysis. This ﬁnding was further
conﬁrmed in an independent cohort of Italian cases [6].
Other associations have been described in small or not re-
plicated studies. In a Dutch cohort of 241 patients with GPA,
a lower proportion of HLA-DR13(6) and HLA-DR1 and an
increased proportion of HLA-DR4 were found compared with
controls [29]; no replication of these data has been published
so far. In two small cohorts of 32 African-American and
74 Caucasian patients, an association with HLA-DRB1 was
documented in PR3-ANCA-positive patients, but not in the
MPO-positive ones [30]; interestingly, an association with a
variation in the same HLA locus has been documented in a
cohort of 152 Chinese patients with GPA and MPA [31]. Rela-
tively small studies documented an association of GPA with
HLA-B50, HLA-DR1, HLA-DR9, HLA-DQw7 and HLA-DR3
[32–34].
In MPA, few data are available; the most interesting report
is from a group of 50 MPO-ANCA-positive Japanese patients,
where an association with the HLA-DRB1*0901 (P = 0.033)
and HLA-DQB1*0303 (P = 0.022) was documented. The small
numbers and the high linkage disequilibrium between the two
alleles (D0 0.95, r2 = 0.82) did not allow the identiﬁcation of
the independent variant [11]. Quite interesting is the conﬁrm-
ation of the association of the HLA-DQB1 with anti-MPO-
positive patients emerged from the EVGC GWAS in a third
cohort of different ethnicity. A study performed with 107
Chinese patients with MPA showed another potential associ-
ation with HLA-DRB1*1101 (P = 0.023) [31]; further studies
will need to clarify if this is a genuine association or only
expression of a non-random inheritance of this allele as part
of a haplotype with a speciﬁc HLA-DQB1.
In EGPA, the most robust association that has emerged so
far is that with HLA-DRB4; this has been shown in an Italian
study with 48 patients (OR 2.49, P = 0.000232) [13] and has
been replicated in an independent study of 102 German EGPA
subjects (OR 1.87, P = 0.0002) [12].
In summary, the ﬁndings of an association for all AAVs
with SNPs in the HLA region have conﬁrmed the existence of
a likely autoimmune component in their pathogenesis. Differ-
ent loci in the HLA region seem to be involved in the different
AAV subtypes, thus suggesting that they have a distinct genetic
background. Moreover, the results of the EVGC GWAS seem to
support a genetic distinction between AAV forms, which is
more closely related to ANCA speciﬁcity rather than to the clin-
ical diagnosis.
PRTN3—SERPINA1 genes
The presence of autoantibodies against the neutrophil
serum protease PR3 suggested its potential role in the develop-
ment of GPA. PR3 may be stored in the neutrophil azurophilic
granules as well as exposed on the neutrophil cell membrane
[35]. Interestingly, PR3 surface expression is bimodal, with
the antigen present on the surface of a proportion of the
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Table 1. Main genetic associations with AAV excluding those deriving from GWASs
Gene Variation Population Cases Controls OR P-value Author, year (reference)
CD226 rs763361 German 642 GPA 1226 1.02 0.016 Wieczorek, 2009 [8]
CTLA4 rs3087243 British 641 (GPA, MPA and EGPA) 9.115 1.19 6.4 × 10−3 Carr, 2009 [9]
GHSR Haplotype German 460 GPA 878 1.30 0.026 Wieczorek, 2010 [10]
HLA-DQB1*0303 Japanese 50 MPA 77 2.35 0.017 Tsuchiya, 2006 [11]
HLA-DRB1*04 German 102 EGPA 341 0.10 0.0028 Wieczorek, 2008 [12]
HLA-DRB1*07 Italian 48 EGPA 350 2.42 0.0042 Vaglio, 2007 [13]
HLA-DRB1*07 German 102 EGPA 341 1.57 0.046 Wieczorek, 2008 [12]
HLA-DRB1*0901-DQB1*0303 Japanese 50 MPA 77 2.44 0.0037 Tsuchiya, 2006 [11]
HLA-DRB1*13 German 102 EGPA 341 0.50 0.019 Wieczorek, 2008 [12]
HLA-DRB3 Italian 48 EGPA 350 0.54 0.028 Vaglio, 2007 [13]
HLA-DRB3 German 102 EGPA 341 0.04 0.004 Wieczorek, 2008 [12]
HLA-DRB4 Italian 48 EGPA 350 2.49 0.00023 Vaglio, 2007 [13]
HLA-DRB4 German 102 EGPA 341 0.10 0.0002 Wieczorek, 2008 [12]
IL-10 Haplotype German 103 EGPA 507 2.16 0.0003 Wieczorek, 2008 [14]
IL2RA rs41295061 British 675 (GPA, MPA and EGPA) 8.936 0.05 0.012 Carr, 2009 [15]
IRF5 Haplotype German 664 GPA 952 0.05 0.0012 Wieczorek, 2010 [16]
KIR2 DS3 Japanese 43 MPA 239 0.24 0.038 Miyashita, 2006 [17]
LEPR Lys656Asn German 460 GPA 878 0.05 0.0013 Wieczorek, 2010 [10]
LEPR Lys656Asn German 196 EGPA 878 1.41 0.0067 Wieczorek, 2010 [10]
LILRA2 rs2241524 AA genotype Japanese 50 MPA 284 2.52 0.049 Mamegano, 2008 [18]
PTPN22 rs2476601 German 199 GPA 399 1.08 0.002 Jagiello, 2005 [19]
PTPN22 rs2476601 Italian 143 GPA, 102 MPA and 99 EGPA 945 1.91 GPA; 2.31
ANCA + GPA
0.005 GPA; 0.00012
ANCA + GPA
Martorana, 2012 [20]
PTPN22 rs2476601 British 641 (GPA, MPA and EGPA) 9.115 1.04 0.000140 Carr, 2009 [9]
TLR9 3-SNP haplotype German, Dutch, British 646 GPA, 164 EGPA and 53 MPA German;
273 GPA, 53 EGPA and 100 MPA Dutch
and British AAV cases
1898 0.60 0.000044 Husmann, 2013 [21]
FCGR3B CNVs High CNVs British 556 (GPA, MPA and EGPA) 286 / 1 × 10−8 Willcocks, 2008 [22]
FCGR3B CNVs Low CNVs British 76 MPA 190 / 0.0003 Fanciulli, 2007 [23]
All genetic association studies on MPA and EGPAwere reported, whereas for GPA we only included studies with a sample size of >400 patients.
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neutrophils (deﬁned as mPR3+), but not on all of them
(mPR3−). The membrane-bound form is the one able to inter-
act directly with the ANCA [36], precipitating neutrophil acti-
vation and their endothelial adhesion. Neutrophil priming is a
key process in order to increase surface expression of PR3 in
the subgroup of mPR3+ neutrophils [37], but the proportion
of mPR3+ and mPR3− cells remains stable over time. A
phenotype with a high proportion of mPR3+ neutrophils is
more frequent in patients with AAV when compared with
controls (85 versus 55%) [38]. These observations, together
with the demonstration of the high stability over time of the
ratio of mPR3+/mPR3− neutrophils in controls (r = 0.94) and
the high concordance of this proportion in monozygotic twins
(r = 0.99) but not in dizygotic twins (r = 0.06) [39], have sug-
gested that the cell surface expression of PR3 is genetically
determined.
A non-replicated study that screened the coding and pro-
moter sequences of PRTN3 (the gene encoding PR3) in 79
GPA patients and 129 controls demonstrated an association
between the disease and an SNP of the promoter region
(A564G) affecting a transcription factor-binding site (OR 4.2,
P < 0.00001) [40]. The association of the PRTN3 gene SNP
rs62132295 has also been interrogated in the EVGC GWAS,
where a subgroup analysis revealed that it was signiﬁcantly as-
sociated with GPA (OR 0.78, P = 2.6 × 10−5). As observed for
the above-mentioned HLA association, the strength of the
PRTN3 SNP signal increased in the PR3-ANCA-positive
subgroup, independently of the clinical diagnosis (OR 0.73,
P = 2.6 × 10−7). No association with PRTN3 emerged in the
MPO-ANCA-positive patients [6], which indicates a role for
PRTN3 only in the pathogenesis of anti-PR3-positive AAV.
PR3 is also central in mediating direct tissue damage after
neutrophil activation has occurred and the enzyme is released
from the cell. Alpha-1 antitrypsin, encoded by the gene
SERPINA1 on chromosome 14, represents the major inhibitor
of PR3 activity. Two alpha-1 antitrypsin alleles, Z and S, have
been described as associated with low enzymatic activity;
studies in small cohorts suggested an association of both of
these alleles with GPA [41–43]. The mechanism behind this
was, and still is, unclear: it has been proposed that an
Table 2. Main genetic associations with AAV deriving from the two GWASs
Gene Variation Population Cases Controls OR P-value
GWAS performed by the EVGC (Lyons et al. 2012) [6]
HLA-DP rs3117242 European 2267 GPA and MPA 6858 3.67 1.5 × 10−71
HLA-DQ rs5000634 European 2267 GPA and MPA 6858 0.80 2.9 × 10−9
COL11A2 rs3130233 European 2267 GPA and MPA 6858 1.51 7.8 × 10−15
COL11A2 rs3117016 European 2267 GPA and MPA 6858 1.83 6.4 × 10−24
SERPINA1 rs7151526 European 2267 GPA and MPA 6858 0.59 2.4 × 10−9
HLA-DP rs3117242 European 1683 GPA 6858 5.39 3.1 × 10−85
HLA-DQ rs5000634 European 1683 GPA 6858 0.83 2.2 × 10−6
ARHGAP18 rs1705767 European 1683 GPA 6858 0.78 3.3 × 10−7
SERPINA1 rs7151526 European 1683 GPA 6858 0.54 4.4 × 10−10
PRTN3 rs62132295 European 1683 GPA 6858 0.78 2.6 × 10−5
MOSPD2 rs6628825 European 1683 GPA 6858 0.80 2.6 × 10−6
HLA-DP rs3117242 European 489 MPA 6858 1.60 1.3 × 10−3
HLA-DQ rs5000634 European 489 MPA 6858 0.67 1.4 × 10−5
ARHGAP18 rs1705767 European 489 MPA 6858 0.84 1.8 × 10−2
SERPINA1 rs7151526 European 489 MPA 6858 0.76 1.7 × 10−1
PRTN3 rs62132295 European 489 MPA 6858 0.99 9.3 × 10−1
MOSPD2 rs6628825 European 489 MPA 6858 0.79 2.2 × 10−1
HLA-DP rs3117242 European 1521 PR3+ 6858 7.03 6.2 × 10−89
HLA-DQ rs5000634 European 1521 PR3+ 6858 0.86 3.3 × 10−5
ARHGAP18 rs1705767 European 1521 PR3+ 6858 0.73 5.2 × 10−8
SERPINA1 rs7151526 European 1521 PR3+ 6858 0.53 5.6 × 10−12
PRTN3 rs62132295 European 1521 PR3+ 6858 0.73 2.6 × 10−7
MOSPD2 rs6628825 European 1521 PR3+ 6858 0.77 6.1 × 10−7
HLA-DP rs3117242 European 556 MPO+ 6858 1.55 3.2 × 10−2
HLA-DQ rs5000634 European 556 MPO+ 6858 0.65 2.1 × 10−8
ARHGAP18 rs1705767 European 556 MPO+ 6858 0.87 1.0 × 10−2
SERPINA1 rs7151526 European 556 MPO+ 6858 0.84 2.8 × 10−1
PRTN3 rs62132295 European 556 MPO+ 6858 1.10 2.2 × 10−1
MOSPD2 rs6628825 European 556 MPO+ 6858 0.86 6.3 × 10−1
GWAS performed by the VCRC (Xie et al. 2013) [7]
HLA-DPB1 rs9277554 European descent 750 GPA 1820 0.24 1.92 × 10−50
HLA-DPA1 rs9277341 European descent 750 GPA 1820 0.33 2.18 × 10−39
WSCD1 rs7503953 European descent 750 GPA 1820 1.50 1.93 × 10−7
COBL rs1949829 European descent 750 GPA 1820 1.78 4.19 × 10−7
CCDC86 rs595018 European descent 750 GPA 1820 1.46 1.60 × 10−7
DCTD rs4862110 European descent 750 GPA 1820 1.44 2.14 × 10−6
SEMA6A rs26595 European descent 750 GPA 1820 0.74 2.09 × 10−8
HLA-DPB1 rs9277554 European descent 578 C-ANCA+ 1820 0.16 4.7 × 10−57
HLA-DPA1 rs9277341 European descent 578 C-ANCA+ 1820 0.27 2.30 × 10−42
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enhanced reactivity of the immune system against an insufﬁ-
ciently cleared PR3 might play a central role [44]; however,
other evidence draws attention to the insufﬁcient inhibition of
the PR3 protease activity in peripheral tissues as responsible
for more severe damage rather than a role as a proper risk
factor for the development of the disease [45]. The largest
study performed in the pre-GWAS era screened 433 Caucasian
patients with GPA and 421 controls, and compared the fre-
quency of the Z and S alleles, showing in 10 patients carrying
the SS, ZZ or SZ genotypes an OR for the development of
GPA of 14.58 (P = 0.002); the small number of cases was re-
sponsible for a broad conﬁdence interval, suggesting caution
in the interpretation of these ﬁndings [46]. In this context, sig-
niﬁcant results came from the results of the EVGC GWAS,
which showed the association of a SNP in the SERPINA1 gene
with AAVs (OR 0.59, P = 2.4 × 10−9). As per PRTN3 ﬁndings,
this association was stronger in GPA patients (OR 0.54, P =
4.4 × 10−10) and even more signiﬁcant in the PR3-ANCA-
positive subgroup, independently of the clinical diagnosis (OR
0.53, P = 5.6 × 10−12) [6]. The tag SNP identiﬁed in the GWAS
is in linkage disequilibrium with the Z allele, conﬁrming that
this can be a risk factor for the development of the disease.
Fine mapping of the PRTN3 and SERPINA1 area is required
for a better understanding of the genetic variations responsible
for the risk of developing GPA and for further improvement in
the pathogenic understanding.
Other replicated associations—PTPN22 and CTLA4
The interaction between ANCA and neutrophils is a central
pathogenetic event in AAV. However, this represents only one
component of a more complex picture. The role of B cells is
also pivotal, as shown by the effectiveness of the anti-CD20
agent rituximab as a therapeutic option [47]. ANCA produc-
tion is one of several B cell functions in AAV; these cells also
provide T-cell support acting as antigen-presenting cells and
are able to produce pro-inﬂammatory cytokines [48]. T-cells
are also heavily involved as proven by their general hyperactiv-
ity in AAV and by the prominent role of the CD4+ T effector
memory cells in causing endothelial damage [49]. It is there-
fore not surprising that SNPs within genes encoding B- and
T-cell-speciﬁc proteins have been identiﬁed as potential risk
factors for AAV.
The gene PTPN22 encodes the lymphoid tyrosine phos-
phatase (Lyp). Abnormal regulatory CD4 T-cell (Treg) func-
tion, increased humoral activity [50] and enhanced neutrophil
functions [51] have been described as features of the 620W
PTPN22 variant; its role in AAV seemed indeed reasonable
and provided the basis for the three main PTPN22 genetic as-
sociation studies performed so far. The ﬁrst, which included a
German cohort of 199 GPA patients and 399 controls, showed
an association of this variant with the disease (OR 1.75, P =
0.002); the association was even more signiﬁcant in the
ANCA-positive subgroup (OR 2.01, P = 0.0002) [19]. This
result has been subsequently replicated in two independent
cohorts of 641 British (OR 1.40, P = 1.4 × 10−4) [9] and 344
Italian AAV patients [20]. Interestingly, the latter study
showed that the association was restricted to the 143 GPA
patients (OR 1.91, P = 0.005), but that the frequency of the
620W PTPN22 variant was comparable between the controls
(n = 945) and the 102 MPA (P = 0.1072) or the 99 EGPA pa-
tients (P = 0.1508). The GPA population was PR3-ANCA-
positive in nearly 80% of the cases, whereas the MPA subgroup
was MPO-ANCA-positive in ∼90%.
CTLA4 is an inhibitory glycoprotein expressed on activated
T cells, which competes with the co-stimulatory molecule
CD28 for the binding of CD80 or CD86 on the antigen-
presenting cells [52]. The monoclonal antibody abatacept,
whose efﬁcacy in controlling disease activity was demonstrated
in a recent trial in GPA patients with non-severe manifestations
[53], contains the binding domain of CTLA4, thus reducing the
interaction CD28–CD80/CD86 and therefore T-cell stimula-
tion. A role for genetic variants in the CTLA4 gene or other
genes involved in its pathway may therefore be of interest in
AAV [54, 55]. The more robust ﬁnding so far involves the SNP
rs3087243, interrogated in two large cohorts of British patients;
the ﬁrst study found an association in 222 AAV patients (P =
0.0001) [56], and the second conﬁrmed it in an independent
cohort of 641 AAV patients (P = 6.4 × 10−3) [9].
Other associations
The VCRC GWAS in AAV identiﬁed a potential association
of GPA with the gene SEMA6A (P = 2.09 × 10−8) encoding
the protein semaphorin 6A [7]. The function of the proteins
belonging to this family is unclear, but it has been proposed
that they may be involved in immune regulation [57]. The as-
sociation between the rs26595 SNP of the SEM6A gene and
GPA was recently investigated also in a different cohort of
Northern European patients, including 879 GPA, 150 MPA
and 191 EGPA [58]. No statistically signiﬁcant difference in
allele frequencies was observed in this group, suggesting the
necessity of further studies to better clarify the role of this
region in AAV.
IL10 is a cytokine with anti-inﬂammatory activity. A study
performed on 32 patients and replicated on 125 additional
cases proposed an association of its (−1082) SNP in GPA [59,
60]; interestingly, the latter report showed a signal for the
same SNP in 36 MPA patients (P < 0.00001) [60]. A subse-
quent, larger study performed on 403 German GPA patients
did not conﬁrm this ﬁnding, but showed an association with
a speciﬁc IL10 haplotype (P = 0.0003) in 75 patients with
ANCA-negative EGPA [14].
The high-afﬁnity IL2 receptor, encoded by the gene IL2RA,
is expressed not only on activated T cells, but also on activated
B cells, NK cells and monocytes [61]. A normal IL2–IL2RA
pathway is central for a physiological function of the immune
system and for the development of a normal Treg repertoire
[62]. A weak association (P = 0.0122) has been documented in
670 British patients with AAV for the SNP rs41295061 [15];
replication in an independent cohort is required before consid-
ering this SNP as a potential risk factor.
CD226 is an adhesion molecule belonging to the immuno-
globulin superfamily. In vitro stimulation of CD226 potenti-
ates NK-mediated cytotoxicity [63] and provides a positive co-
stimulatory signal for T-cell proliferation. An association
between CD226 and GPA was documented in two distinct
cohorts of 520 and 122 German GPA patients (respectively,
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OR 1.2; P = 0.020 and OR 1.37, P = 0.020); however, further
replication failed in 105 British GPA patients [8]. A further in-
dependent replication study on a cohort of 641 British AAV
cases found no association (P = 0.21) [9]. Interestingly, the two
populations were of similar size and showed similar frequency
of the SNP analysed (0.47 versus 0.50), suggesting as unlikely a
different effect of the SNP in these populations.
Fc gamma receptors (FCGRs) are a group of proteins ex-
pressed on the surface of different cell types with different af-
ﬁnity for the Fc portion of different IgG subclasses [64],
suggesting a reasonable potential role for FCGRs in AAV.
However, the genes encoding these receptors are located in a
highly variable area (locus 1q23.3), whose genotyping has
proven challenging due to high variability in terms of SNPs
and copy number variations (CNVs) [64]. A Dutch study
identiﬁed a SNP of FCGR2A and FCGR3A as potential risk
factors for GPA in a cohort of 91 patients [65], but the ﬁnding
was not conﬁrmed, at least for the FCGR2A SNP, in a cohort
of 107 British patients [66]. CNVs of FCGR3B have been in-
vestigated in two cohorts of patients with contrasting results:
an association was documented using qPCR in 80 UK patients
with GPA and replicated in 77 French and 76 MPA patients
[23]. However, this was not conﬁrmed in 567 AAV patients
when a different approach was used (paralogue ratio test) [67].
The availability of new genotyping techniques will shed light
on the potential association of this complex area with AAV.
Interferon regulatory factor 5 (IRF5) is a transcriptional
factor able to induce transcription of IFN-alpha mRNA [68].
A large association study on 644 GPA failed to identify an as-
sociation between IRF5 SNPs and disease; however, a potential
protective haplotype was identiﬁed (P = 0.0012) [16]. Interest-
ingly, one of these SNPs (rs10954213) has been recently iden-
tiﬁed as in association with MPO-ANCA-positive AAV in 177
Japanese patients (OR 1.27, P = 0.023) [69].
A well-established role in the development of AAVs is
played by infection. Any chronic infection, particularly nasal
carriage of Staphylococcus aureus, is considered a potential
trigger of the disease [70]. Toll-like receptors (TLRs) are a
group of proteins able to recognize microbiological structures
and activate immune responses. SNPs of TLR9 have been
shown to be associated with GPA, MPA and PR3-associated
AAV in a cohort of 863 AAV patients; however, the ﬁndings
were not replicated in a small independent cohort. Interesting-
ly, MPO-ANCA-positive disease was associated with the
contrary allele compared with the PR3-ANCA subset, leading
to a signiﬁcant difference between the two groups for the SNP
rs352140 (P = 0.000016) [21]. Defensins are cationic proteins
characterized by intrinsic antimicrobial activity [71]; a weak
association between CNVs of the defensin gene DEFB4 and
GPA has been documented in a small cohort of Chinese
patients [72].
Few further associations have been documented so far. In a
cohort of 460 GPA patients, an association with a leptin SNP
was found and replicated in 226 patients (OR 0.72 P = 0.0013);
interestingly, genotyping of the same SNP in 196 EGPA pa-
tients conﬁrmed the association but with contrasting allele dis-
tribution (OR 1.41, P = 0.0067) [10]. A small Japanese study
identiﬁed a weak association between a leucocyte immunoglobu-
lin-like receptor (LILRA2) and MPA (P = 0.049) [18]; ﬁnally,
genetic variants of genes encoding complement proteins C3F
and C4A3 have been associated with AAV in 67 patients [73].
GENETIC FINDINGS AND DISEASE
PHENOTYPES
Genetic studies have been fundamental for the understanding
of AAV so far. They have conﬁrmed that the single disease en-
tities grouped under the umbrella of AAV may reasonably be
considered distinct diseases also because of their different
genetic background. Moreover, it is now quite clear how GPA
and MPA may be more correctly re-deﬁned according to the
ANCA speciﬁcity (PR3 versus MPO) rather than on the basis
of their clinical phenotype. This is not surprising since several
clinical ﬁndings were already pointing towards that direction,
such as the different prognosis associated with anti-PR3 or
anti-MPOANCA positivity [74] as well as the different cardio-
vascular risk between these groups and the higher proportion
of extrarenal manifestation in anti-PR3-positive patients [75–
81] (Table 3). These studies have also conﬁrmed the central
role of autoimmunity in AAV, as evidenced by the strong asso-
ciation with HLA and SNPs typical of other autoimmune dis-
eases. More detailed are at the moment the evidences available
for GPA—easier to study given its higher prevalence—where a
crucial role has been shown also for the autoantigen PR3 and
for its main inhibitor alpha-1 antitrypsin.
Although very informative, all these ﬁndings represent only
the beginning of a new exciting and dynamic phase in this ﬁeld.
Table 3. Major distinctive clinical features between PR3-ANCA and MPO AAV (irrespective of the clinical diagnosis)
Variable PR3-ANCA MPO-ANCA Author, year (reference)
Mean age at onset (years) 56–59 62–65 de Joode, 2013 [76]; Quintana, 2014 [77]
Male gender 66% 48% de Joode, 2013 [76]
ENT involvement 77% 23% de Joode, 2013 [76]
Eye involvement 40% 15% Franssen, 1998 [78]
Kidney-limited disease 2% 31% de Joode, 2013 [76]
Interstitial lung disease 0 7.2%a Arulkumaran, 2011 [79]
Relapse (hazard ratio of relapse of PR3+ versus MPO+ patients) 1.89 (95% CI 1.33–2.69) Lionaki, 2012 [80]
Relapse (relapse-free patients 5 years after diagnosis) 32% 60% Lionaki, 2012 [80]
Cardiovascular risk (patients with ≥1 cardiovascular event over 5-year follow-up) 6.6% 19.2% Suppiah, 2011 [81]
aThis percentage was calculated out of the patients with MPA (14/194 MPA patients studied had interstitial lung disease); all patients with interstitial lung disease were MPO-ANCA-
positive.
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The next step will be to analyse larger GWASs or association
studies in patients with anti-PR3 and anti-MPO AAV as separ-
ate entities in order to be more powered for the identiﬁcation of
further antibody-speciﬁc associations. The collection of larger
cohorts or the metanalysis of data deriving from different exist-
ing cohorts will probably be of help also in identifying predis-
posing variants shared by the different ANCA subsets, which is
quite expected given the signiﬁcant clinical overlap between
anti-PR3 and anti-MPO AAVs. The enrolment of patients in
national and international registries characterized by long
follow-up and detailed clinical data will make longitudinal
studies possible for the identiﬁcation of genetic predictors of
disease severity and clinical outcome. A GWAS in EGPA is def-
initely warranted to allow an improvement in the understanding
of the disease and only the cooperation of several centres will
allow a sufﬁciently powered approach.
We should not forget that the identiﬁcation of an associ-
ation between a tag SNP and a disease could be ﬂag of an
association present somewhere in the identiﬁed area, but po-
tentially related to other variants in linkage disequilibrium
with the SNP analysed. Fine mapping approaches are therefore
necessary for the identiﬁcation of the real associations and this
may, in the long term, allow for the development of more tar-
geted therapeutic approaches.
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